The board of directors of the Jacobio Pharmaceuticals Group Co., Ltd. announce that the Company has received Investigational New Drug (IND) approval of its self-developed drug JAB-26766 (PARP7 inhibitor) from the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA) in China. The Group plans to initiate a Phase I/IIa advanced solid tumors clinical trial in China. PARP7 inhibitors target immuno-oncology (I/O) signaling pathway and can be used to treat various solid tumors such as squamous non-small cell ling cancer (NSCLC), and head and neck squamous cell carcinomas (HNSCC).

Studies show that PARP7 inhibitors have the potential to directly inhibit tumor growth and enhance the anti-tumor immune response. JAB-26766 is an orally administered small-molecule with significant anti-tumor activity against a variety of tumor models in mice. PARP7 is located downstream of STING signaling pathway, and JAB-26766 has potential to combine with Jacobio's self-developed CD73 STING-iADC.

JAB-26766 also has the potential to be used in combination with PD-(L)1 monoclonal antibodies to bring more treatment options to patients. Jacobio is committed to developing global first-in-class drugs, and key programs are targeting the top three worldwide. As of the date of this announcement, there is only one PARP7 inhibitor in Phase I clinical stage globally.